Jon M. Huibregtse

Dr. Jon M. Huibregtse

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Molecular Cell
Verified
Journal Article
Closed access
CSCaleb D. Swaim
Caleb D. Swaim
ASAriella F. Scott
Ariella F. Scott
LCLarissa A. Canadeo
Larissa A. Canadeo
JHJon M. Huibregtse
Jon M. Huibregtse

1 May 2013 in Molecular Cell
Verified
Journal Article
Closed access
FWFeng Wang
Feng Wang
LDLarissa A. Durfee
Larissa A. Durfee
JHJon M. Huibregtse
Jon M. Huibregtse

1 June 2020 in Cell Reports
Verified
Journal Article
Open access
CSCaleb D. Swaim
Caleb D. Swaim
LCLarissa A. Canadeo
Larissa A. Canadeo
KMKristen J. Monte
Kristen J. Monte
SKSwati Khanna
Swati Khanna
DLDeborah J. Lenschow
Deborah J. Lenschow
JHJon M. Huibregtse
Jon M. Huibregtse
ISG15 is a ubiquitin-like modifier that also functions extracellularly, signaling through the LFA-1 integrin to promote interferon (IFN)-γ release from natural killer (NK) and T cells. The signals that lead to the production of extracellular ISG15 and the relationship between its two core functions remain unclear. We show that both epithelial cells and lymphocytes can secrete ISG15, which then signals in either an autocrine or paracrine manner to LFA-1-expressing cells. Microbial pathogens and Toll-like receptor (TLR) agonists result in both IFN-β-dependent and -independent secretion of ISG15, and residues required for ISG15 secretion are mapped. Intracellular ISGylation inhibits secretion, and viral effector proteins, influenza B NS1, and viral de-ISGylases, including SARS-CoV-2 PLpro, have opposing effects on secretion of ISG15. These results establish extracellular ISG15 as a cytokine-like protein that bridges early innate and IFN-γ-dependent immune responses, and indicate that pathogens have evolved to differentially inhibit the intracellular and extracellular functions of ISG15.

27 October 2015 in EMBO Reports
Verified
Journal Article
Open access
PDF file
HOHazel F O'COnnor
Hazel F O'COnnor
NLNancy Lyon
Nancy Lyon
JLJustin Leung
Justin Leung
PAPoonam Agarwal
Poonam Agarwal
CSCaleb D Swaim
Caleb D Swaim
JHJon M. Huibregtse
Jon M. Huibregtse
We describe a new class of reagents for identifying substrates, adaptors, and regulators of HECT and RING E3s. UBAITs (Ubiquitin‐Activated Interaction Traps) are E3‐ubiquitin fusion proteins and, in an E1‐ and E2‐dependent manner, the C‐terminal ubiquitin moiety forms an amide linkage to proteins that interact with the E3, enabling covalent co‐purification of the E3 with partner proteins. We designed UBAITs for both HECT (Rsp5, Itch) and RING (Psh1, RNF126, RNF168) E3s. For HECT E3s, trapping of interacting proteins occurred in vitro either through an E3 thioester‐linked lariat intermediate or through an E2 thioester intermediate, and both WT and active‐site mutant UBAITs trapped known interacting proteins in yeast and human cells. Yeast Psh1 and human RNF126 and RNF168 UBAITs also trapped known interacting proteins when expressed in cells. Human RNF168 is a key mediator of ubiquitin signaling that promotes DNA double‐strand break repair. Using the RNF168 UBAIT, we identify H2AZ—a histone protein involved in DNA repair—as a new target of this E3 ligase. These results demonstrate that UBAITs represent powerful tools for profiling a wide range of ubiquitin ligases.

1 July 2015 in Biochimie
Verified
Journal Article
Closed access
FWFeng Wang
Feng Wang
LCLarissa A. Canadeo
Larissa A. Canadeo
JHJon M. Huibregtse
Jon M. Huibregtse

2 October 2021 in iScience
Verified
Journal Article
Open access
CSCaleb D. Swaim
Caleb D. Swaim
VDVarun Dwivedi
Varun Dwivedi
YPYi-Chieh Perng
Yi-Chieh Perng
XZXu Zhao
Xu Zhao
LCLarissa A. Canadeo
Larissa A. Canadeo
JHJon M. Huibregtse
Jon M. Huibregtse
The emergence of SARS-CoV-2 has led to a global health crisis that, in addition to vaccines and immunomodulatory therapies, calls for the identification of antiviral therapeutics. The papain-like protease (PLpro) activity of nsp3 is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG), an orally available and widely available generic drug, inhibits SARS-CoV-2 replication in Vero-E6 cells with an EC50 of approximately 2 μM. 6-TG also inhibited PLpro-catalyzed polyprotein cleavage and de-ISGylation in cells and inhibited proteolytic activity of the purified PLpro domain in vitro. We therefore propose that 6-TG is a direct-acting antiviral that could potentially be repurposed and incorporated into the set of treatment and prevention options for COVID-19.